Videos

Helen L. Bernie, DO, MPH, discusses how expanded TRT labeling could improve care for men with idiopathic hypogonadism.

Nannan Thirumavalavan, MD, reflects on how the FDA’s testosterone labeling changes, informed by the TRAVERSE trial, have influenced TRT prescribing and clinician confidence over the past year.

Daniel J. George, MD, highlights survey findings on the role of caregivers in the treatment journey for patients with metastatic prostate cancer.

In this video, Dalia Kaakour, MD, MPH, highlights retrospective findings on the use of ctDNA in detecting residual disease and recurrence in testicular cancer.

In this video, Meri-Margaret Deoudes discusses ongoing challenges for patients with bladder cancer, including costs of care, delayed diagnoses among women, and access barriers among patients in rural areas.

PSMA PET scans reshape prostate cancer care—learn who should interpret results, how reports vary, and why a team approach guides treatment.

Learn how emerging advanced scans outpace CT and bone scans in finding micrometastatic prostate cancer and shaping treatment teamwork.

C. Shawn West, MD, provides an overview of the pre-MIST era in BPH management, highlighting the reliance on invasive surgical approaches and the clinical and patient-centered limitations that drove innovation.

Suction-enabled URS platforms and AI-driven prediction and planning tools represent 2 parallel frontiers in kidney stone management, with active fragment evacuation already in clinical use and artificial intelligence poised to reshape preoperative planning, patient selection, and intraoperative guidance.

In this segment, Dr. Charles J. Ryan invites the panel to discuss how clinicians interpret clinical trial results in the context of real world patient populations with metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan leads a panel discussion with Dr. Alan H. Bryce, Dr. Murilo De Almeida Luz, and Dr. Jayram on key clinical considerations that influence treatment selection when intensifying therapy for metastatic castration sensitive prostate cancer (mCSPC).

David R. Wise, MD, PhD, discusses the potential for pasritamig combined with docetaxel to improve outcomes in patients with mCRPC.

Robert Flavell, MD, PhD, and Anil P. Bidkar, PhD, discuss the synergistic potential of CD46-directed alpha radiation and ADC therapy combination.

Akanksha Mehta, MD, MS, discusses AUA guideline recommendations for performing post-vasectomy semen analysis.

Neha Vapiwala, MD, FASTRO, discusses the integration of radiation therapy with systemic treatment intensification across different stages of localized and locally advanced prostate cancer.

Experts discuss the implications of the FDA’s potential pathway to expand testosterone replacement therapy labeling for low libido in men with idiopathic hypogonadism.

In the final episode, ‘Advice for Integrating PSMA PET Imaging in Advanced Prostate Cancer,’ the panelists share practical advice for incorporating PSMA PET into prostate cancer clinics and workflows.

Kyle M. Rose, MD, discusses key considerations for optimizing the timing and sequencing of inguinal and pelvic lymph node dissection.

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss how clinicians interpret data from pivotal phase 3 clinical trials evaluating androgen receptor pathway inhibitors used in combination therapy for metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan invites Dr. Jayram and Dr. Alan H. Bryce to discuss how potential central nervous system effects influence treatment selection in metastatic castration sensitive prostate cancer (mCSPC).

Akanksha Mehta, MD, MS, discusses updated recommendations from the 2026 AUA Vasectomy Guideline on vas isolation and occlusion techniques.

Fred Saad, MD, FRCS, discusses findings from a post hoc analysis of the phase 3 ARANOTE trial.

Medtronic's Touch Surgery enterprise platform, integrated with the Hugo robotic system, offers AI-driven case segmentation, real-time anatomic overlay, and two-way telementoring capabilities that James R. Porter, MD, describes as the most robust digital offering currently available on a robotic surgery platform.

Meri-Margaret Deoudes discusses findings from BCAN's New Faces of Bladder Cancer Report.

Daniel J. George, MD, highlights patient-reported outcomes and tolerability findings from the phase 3 CAPItello-281 trial, evaluating the addition of capivasertib to abiraterone in patients with PTEN-deficient de novo mHSPC.

Minas P. Economides, MD, discusses the evolving role of biomarkers such as KIM-1 in refining risk stratification and highlighted emerging innovations that may reshape how kidney cancer is both imaged and therapeutically targeted.

In this video, Jennifer Miles-Thomas, MD, recaps a SUFU 2026 discussion on leveraging surgeon–APP collaborations in urology.

In this episode, ‘Clinical Reliability of PSMA PET in Advanced Prostate Cancer,’ expert faculty examine the real-world reliability of PSMA PET imaging in evaluating tumor burden and disease extent in advanced prostate cancer.